At a user meeting, Oxford Nanopore gave an update on what it has been working on.
Developed by University of Texas researchers, the method is one of a small but growing number of efforts to develop single-molecule protein analysis techniques.
Researchers have been developing nanopore metagenomic sequencing protocols to enable real-time outbreak surveillance outside the traditional laboratory.
The group plans to use the method to analyze isoform differences of B cell surface receptors, common targets for immunotherapy.
The researchers are testing the method in a clinical trial of hospital-acquired pneumonia and are working on tests for meningitis and prosthetic joint infections.
The Menlo Park, California-based company plans to demonstrate its sequencing technology on a small genome in the near future.
The company plans to use the funding to build beta units of its optical nanopore sequencer for early adopters in industry and academia.
The Beijing-based firm said it will use the funding for research and development, to obtain additional intellectual property, and to pursue its strategic goals.
The company had £13.8 million ($18.4 million) in revenues and a net loss of £56.6 million in 2017.
University of Oxford researchers used DNA scaffolds to build custom peptide nanopores that they said could make nanopore-based protein analysis more feasible.
Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.
The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.
ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.
In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.